NANJING, China, Aug. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2010 on Thursday, August 12, 2010, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, August 12 at 8 p.m. Beijing/Hong Kong time).
To access the conference call, please dial: United States toll-free: +1.866.277.1184 International: +1.617.597.5360 North China toll-free: 10.800.152.1490 South China toll-free: 10.800.130.0399 China toll free / Netcom: 10 800 852 1490 Hong Kong: +852.3002.1672
Please ask to be connected to Q2 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 23060010.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be available by dialing: United States toll-free: +1.888.286.8010 International: +1.617.801.6888
The passcode for replay participants is: 80027885. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
Investor and Media Contacts: Email: email@example.com In Nanjing: Frank Zhao Chief Financial Officer Simcere Pharmaceutical Group Tel: +86-25-8556-6666 x8818 In Beijing: Ruirui Jiang Brunswick Group Tel: +86-10-6566-2256 In the United States: Kate Tellier Brunswick Group Tel: +1-212-333-3810 In Hong Kong: Joseph Lo Chi-Lun Brunswick Group Tel: +852-3512-5000
|SOURCE Simcere Pharmaceutical Group|
Copyright©2010 PR Newswire.
All rights reserved